Exact Mass: 600.3427018
Exact Mass Matches: 600.3427018
Found 500 metabolites which its exact mass value is equals to given mass value 600.3427018,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Phorbol caprate, tiglate
D009676 - Noxae > D002273 - Carcinogens > D010703 - Phorbol Esters
LysoPI(0:0/18:0)
LysoPI(0:0/18:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(0:0/18:0), in particular, consists of one chain of stearic acid at the C-2 position.
LysoPI(18:0/0:0)
LysoPI(18:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(18:0/0:0), in particular, consists of one chain of stearic acid at the C-1 position.
Benzoic acid, 4-(4-((2R,5R)-5-((bis(phenylmethyl)amino)carbonyl)-2-heptyl-4-oxo-3-thiazolidinyl)butyl)-, rel-
4-[3-[3-[Bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
Streptolydigin
PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S))
PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0)
PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R))
PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0)
PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:3(5Z,11Z,14Z)-O(8,9))
PA(8:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0)
PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:3(8Z,11Z,14Z)-O(5,6))
PA(8:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0)
PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0)
PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0)
PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0)
PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0)
PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0)
PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0)
PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0)
PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0)
PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0)
PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9))
PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0)
PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Ranaconitine
12-Ethyl-8-isobutyl-3-vinylbacteriochlorophyllide d
7beta,9alpha,14beta-triacetoxy-3beta-benzoyloxy-12beta,15beta-epoxy-11beta-hydroxyjatropha-5E-ene|euphoheliosnoid E
19-dechloro-ansamitocin P-3|19-deschloroansamitocin P-3
3-(4-Hydroxycinnamoyl)-3alpha-3-Hydroxy-7,9(11)-multifloradien-29-oic acid|bryocoumaric acid
(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2-[(2Z,4E)-decadienoyloxy-6,7-dihydroxy]cleroda-3,12(E),14-triene|argutin C
bufotalin 3-hemisuberate|Korksaeure-mono-<3>bufotalylester|Korksaeure-mono-[3]bufotalylester
6-hydroxy-hardwickiic acid 2-beta-D-glucopyranosylbenzyl ester
12xi-acetoxy-11beta-hydroxypetuniasterone D 7-acetate
(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2,7-dihydroxy-6-[(2Z,4E)-decadienoyloxy]cleroda-3,12(E),14-triene|argutin D
polypodin B-22-O-benzoate|polypodine B-22-O-benzoate
17-hydroxy-euphornin|7beta,9alpha,14beta-triacetoxy-3beta-benzoyloxy-15beta,17-dihydroxyjatropha-5E,11E-diene
(20R,22S)-1-oxo-witha-2,5,24-trienolide-20-beta-ol 20-beta-D-glucopyranoside|glucosomniferanolide
rel-(1R,3S,5R,7S,8R)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-5-(3-methylbut-2-en-1-yl)-3-[5-methyl-2-(1-methylethenyl)hex-4-en-1-yl]-8-(2-methylprop-1-en-1-yl)tricyclo[3,3,1,13,7]decane-2,4,9-trione
21-(E)-coumaroyloxy-5alpha-cycloart-24-ene-3,23-dione
7,8-didehydro-25-anhydrocimigenol-3-beta-D-xylopyranoside
4alpha-acetyl-2beta-angeloyl-5alpha,8-diisobutyryl-1beta,3alpha,10,11-tetrahydroxybisabolene
4alpha-acetyl-2beta-angeloyl-5alpha,10-diisobutyryl-1beta,3alpha,8,11-tetrahydroxybisabolene
16alpha,25-Diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|16alpha,25-diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione|Fabacein
(25S)-26-O-beta-D-xylopyranosyl-5alpha-cholestane-3beta,6alpha,8,15beta,16beta,26-hexaol|lysastroside A
2,16-Di-O-acetylcucurbitacin D|2,16-Di-O-acetylcucurbitacin R|2beta,16alpha-Diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|2beta,16alpha-diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione
1,12,23-trihydroxy-1,6,12,17,23,28-hexazacyclotritriacontane-2,5,13,16,24,27-hexone
C27H48N6O9 (600.3482597999999)
Desferrioxamine E
C27H48N6O9 (600.3482597999999)
A cyclic hydroxamic acid siderophore that is produced by several bacterial species and exhibits antitumour activity.
[2-hydroxy-3-[hydroxy-[2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] octadecanoate
1,12,23-trihydroxy-1,6,12,17,23,28-hexazacyclotritriacontane-2,5,13,16,24,27-hexone [IIN-based on: CCMSLIB00000846839]
C27H48N6O9 (600.3482597999999)
1,12,23-trihydroxy-1,6,12,17,23,28-hexazacyclotritriacontane-2,5,13,16,24,27-hexone [IIN-based: Match]
C27H48N6O9 (600.3482597999999)
Ile Pro Trp Trp
Ile Trp Pro Trp
Ile Trp Trp Pro
Lys Lys Tyr Tyr
Lys Tyr Lys Tyr
Lys Tyr Tyr Lys
Leu Pro Trp Trp
Leu Trp Pro Trp
Leu Trp Trp Pro
Asn Arg Arg Arg
C22H44N14O6 (600.3568084000001)
Pro Ile Trp Trp
Pro Leu Trp Trp
Pro Trp Ile Trp
Pro Trp Leu Trp
Pro Trp Trp Ile
Pro Trp Trp Leu
Arg Asn Arg Arg
C22H44N14O6 (600.3568084000001)
Arg Arg Asn Arg
C22H44N14O6 (600.3568084000001)
Arg Arg Arg Asn
C22H44N14O6 (600.3568084000001)
Trp Ile Pro Trp
Trp Ile Trp Pro
Trp Leu Pro Trp
Trp Leu Trp Pro
Trp Pro Ile Trp
Trp Pro Leu Trp
Trp Pro Trp Ile
Trp Pro Trp Leu
Trp Trp Ile Pro
Trp Trp Leu Pro
Trp Trp Pro Ile
Trp Trp Pro Leu
Tyr Lys Lys Tyr
Tyr Lys Tyr Lys
Tyr Tyr Lys Lys
Streptolydigin
A monocarboxylic acid amide that is a broad-spectrum antibiotic produced by Streptomyces lydicus. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
4-[3-[3-[Bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D058891 - 5-alpha Reductase Inhibitors
3-beta-O-(E)-coumaroyl-D:C-friedooleana-7,9(11)-dien-29-oic acid
A pentacyclic triterpenoid that is the cinnamate ester obtained by the formal condensation of trans-4-coumaric acid with D:C-friedoolean-7,9(11)-dien-3beta-ol-29-oic acid. It is isolated from the stems of Lagenaria siceraria and exhibits cytotoxic activity against human hepatoma SK-Hep 1 cells.
Ethyl (4R)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate
1-stearoyl-sn-glycero-3-phospho-1D-myo-inositol
A 1-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 1-acyl group is specified as stearoyl.
2-[(4E)-4-[(2E,4E)-6-(1,4-dimethylspiro[2,9-dioxabicyclo[3.3.1]non-6-ene-8,2-oxirane]-3-yl)-1-hydroxy-4-methylhepta-2,4-dienylidene]-1-(5-hydroxy-6-methyloxan-2-yl)-3,5-dioxopyrrolidin-2-yl]-N-methylpropanamide
2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Benzyl ((2S)-3-(tert-butoxy)-1-(((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)amino)-1-oxobutan-2-yl)carbamate
C32H48N4O7 (600.3522817999999)
(2R)-2-hydroxy-3-[(hydroxy{[(1S,2R,3S,4S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]propyl stearate
[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] octadecanoate
2,3-dihydroxypropyl [3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]-2-hydroxypropyl] hydrogen phosphate
[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-acetyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
(1-heptanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9E,11E,13E)-hexadeca-9,11,13-trienoate
[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[1-phosphonooxy-3-[(E)-tridec-8-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
2-[hydroxy-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-heptanoyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)
6-O-(1-O-Stearoyl-sn-glycero-3-phosphono)-1D-myo-inositol
Ac-Arg-Gly-Lys(Ac)-AMC
C28H40N8O7 (600.3019810000001)
Ac-Arg-Gly-Lys(Ac)-AMC is a substrate for HDAC[1].
(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate
2-{[22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxahexacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹²]tetracosa-4,11,14-trien-9-yl]oxy}oxane-3,4,5-triol
methyl (9s,11r,13r,13's,14z,17r,17'z,20s)-14,17'-diethylidene-16-methyl-1',8,10',16-tetraazaspiro[pentacyclo[9.7.1.1¹³,¹⁷.0²,⁷.0⁸,¹⁹]icosane-9,12'-tetracyclo[11.2.2.0³,¹¹.0⁴,⁹]heptadecan]-1(19),2,3'(11'),4,4',6,6',8'-octaene-20-carboxylate
(2s,4ar,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-(acetyloxy)-9-[(acetyloxy)methyl]-4a-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2-carboxylic acid
1-(3,7-dimethylocta-2,6-dien-1-yl)-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione
(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate
(6s,9s,12s,15s,20as)-9-benzyl-15-[(2s)-butan-2-yl]-1,4,7,10,13-pentahydroxy-12-(hydroxymethyl)-6-isopropyl-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one
n-[2-({[(1s,2s,3s,4s,6s,8s,9r,10s,13s,16s,17s)-11-ethyl-3,8,9-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]oxy}carbonyl)phenyl]ethanimidic acid
7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-(3-methylbuta-1,3-dien-1-yl)-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione
4-(acetyloxy)-10-hydroxy-9a,11a-dimethyl-7-oxo-1-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate
(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl propanoate
7-{4-[({9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-9-ium-7-yl}oxy)carbonyl]-1-phenyl-3,4-dihydro-2h-naphthalene-1-carbonyloxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-9-ium
2-[4-(6-{1,6-dimethyl-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3-en-7-yl}-1-hydroxy-4-methylhepta-2,4-dien-1-ylidene)-1-(5-hydroxy-6-methyloxan-2-yl)-3,5-dioxopyrrolidin-2-yl]-n-methylpropanimidic acid
3,4-dimethoxy-2-(methoxymethyl)-6-[(1,3,4,5-tetramethoxypentan-2-yl)oxy]-5-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]oxane
(2r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione
(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione
(1r,2r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-9a,11a-dimethyl-1-[(2r,5s)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol
(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione
(6r)-6-[(1s)-1-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-4-methyl-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one
4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl 3-(4-hydroxyphenyl)prop-2-enoate
(1r,2r,6s,7s,8r,10s,11s,12r,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-[(1e,3e)-nona-1,3-dien-1-yl]-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl propanoate
3,23-dihydroxy-12-oleanene-28,30-dioic acid; 3β-form,3,23-di-ac,28-me ester
{"Ingredient_id": "HBIN007008","Ingredient_name": "3,23-dihydroxy-12-oleanene-28,30-dioic acid; 3\u03b2-form,3,23-di-ac,28-me ester","Alias": "NA","Ingredient_formula": "C35H52O8","Ingredient_Smile": "NA","Ingredient_weight": "600.78","OB_score": "NA","CAS_id": "88202-34-0","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8408","PubChem_id": "NA","DrugBank_id": "NA"}
(2s)-2-[(2s,4e)-4-[(2e,4e,6r)-6-[(1r,2r,5r,6s,7r)-1,6-dimethyl-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3-en-7-yl]-1-hydroxy-4-methylhepta-2,4-dien-1-ylidene]-1-[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]-3,5-dioxopyrrolidin-2-yl]-n-methylpropanimidic acid
(1r,3s,4s,5s,6e,8r,10r,12s,13s,14s,15s)-8,10,15-tris(acetyloxy)-12-hydroxy-3,7,11,11,14-pentamethyl-16-oxatricyclo[11.2.1.0¹,⁵]hexadec-6-en-4-yl benzoate
n-[2-({[(1s,2r,3r,4s,5s,6s,8r,9r,10s,13s,16s,17r,18s)-11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid
13-(3,7-dimethylocta-2,6-dien-1-yl)-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
methyl (1s,12r,14r,15e,18s)-15-ethylidene-12-[(13r,14e)-14-ethylidene-12-methylidene-1,10-diazatetracyclo[11.2.2.0³,¹¹.0⁴,⁹]heptadeca-3(11),4,6,8-tetraen-6-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
(1r,13r,15s)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
3-(2-{[(2e)-5-[(4-ethenyl-5-hydroxy-3-methyl-2h-pyrrol-2-yl)methyl]-3-(3-methoxy-3-oxopropyl)-4-methylpyrrol-2-ylidene]methyl}-5-{[(3e)-3-ethylidene-5-hydroxy-4-methyl-4h-pyrrol-2-ylidene]methyl}-4-methyl-1h-pyrrol-3-yl)propanoic acid
(1's,2s,3r,4'r,5s,6s,7's,9's,10'e,12'e,14'r,16'e,19'r)-6-[(2e)-but-2-en-2-yl]-3,9'-dihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one
(1s,13s,15s)-5,6-dihydroxy-16,16-dimethyl-13-[(2s)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
6-(1-{9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-4-methyl-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one
n-{2-[({11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methoxy)carbonyl]phenyl}ethanimidic acid
(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-2-{[(2r,3r,3ar,5ar,7s,9ar,9br)-3-hydroxy-6,6,9a-trimethyl-2-(prop-1-en-2-yl)-decahydro-1h-cyclopenta[a]naphthalen-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol
(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4,19-dihydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4,19-dihydroxy-1,9,11,16-tetramethyl-8-[(3r)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
(1r,9s,10r,11r,13s,17r,25s,26r,27s,28z,33s,36s,38z,39r)-28,38-diethylidene-25-methoxy-35-oxa-8,14,24,30-tetraazadodecacyclo[25.5.2.2¹¹,¹⁴.1¹,⁸.1⁹,²⁶.1¹⁰,¹⁷.0²,⁷.0¹³,¹⁷.0¹⁸,²³.0³⁰,³³.0²⁴,³⁶.0²⁶,³⁹]nonatriaconta-2,4,6,18,20,22-hexaene
5-{15-[2-(acetyloxy)-5-hydroxy-4-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl]pentadecyl}-4-hydroxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl acetate
(1's,2s,3r,4'r,5s,6s,7'r,9's,10'e,12'e,14'r,16'e,19'r)-6-[(2e)-but-2-en-2-yl]-3,8',9'-trihydroxy-7'-methoxy-5,6',10',14',16'-pentamethyl-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one
(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-[(1e,3e)-nona-1,3-dien-1-yl]-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl propanoate
6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione
(2s,6r)-6-[(1r,3as,5ar,7r,9as,11r,11ar)-11-hydroxy-7-[(3-methoxy-3-oxopropanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylidene-4-oxoheptanoic acid
17-(acetyloxy)-2,16-dimethyl-5-oxo-15-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate
(2r,3r)-2-[(1s,3as,5as,7r,8s,9ar,9br,11ar)-3a,5a,7,8-tetrahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,6-dihydroxy-6-methylheptan-3-yl benzoate
(1s,13s,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
1-(1r,3r,5s,6r)-6-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3,4-diphenylcyclobutane-1,2-dicarboxylate
3-{2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy}-3-oxopropanoic acid
(2r,3r,4s,5s,6e,8r)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl propanoate
methyl (14z,14'e)-14,14'-diethylidene-16-methyl-1',8,10',16-tetraazaspiro[pentacyclo[9.7.1.1¹³,¹⁷.0²,⁷.0⁸,¹⁹]icosane-9,12'-tetracyclo[11.2.2.0³,¹¹.0⁴,⁹]heptadecan]-1(19),2,3'(11'),4,4',6,6',8'-octaene-20-carboxylate
8,10,15-tris(acetyloxy)-12-hydroxy-3,7,11,11,14-pentamethyl-16-oxatricyclo[11.2.1.0¹,⁵]hexadec-6-en-4-yl benzoate
1,5,12,16,23,27-hexahydroxy-1,6,12,17,23,28-hexaazacyclotritriaconta-5,16,27-triene-2,13,24-trione
C27H48N6O9 (600.3482597999999)
4-(acetyloxy)-3,12-dihydroxy-6-isopropyl-5-[(3-methanesulfinylpropanoyl)oxy]-3,9-dimethyl-13-methylidene-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-9-yl butanoate
(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione
(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione
(2s,3r,4s,5s)-2-{[(1s,3r,8s,10r,17s,18r,19r,21s,22r)-22-(2-hydroxypropan-2-yl)-3,9,9,17,19-pentamethyl-23,24-dioxahexacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁵,¹⁵.0⁸,¹³]tetracosa-5,12,15-trien-10-yl]oxy}oxane-3,4,5-triol
(1s,2r,6r,8r,10r,11s,12s,15r,16r,17s)-17-(acetyloxy)-2,16-dimethyl-5-oxo-15-[(1s)-1-[(1s,3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate
(1s,3s,6s,17s,19s)-6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione
(1r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
(1s,2s,3ar,4s,5s,9r,11r,13as)-4,9,11-tris(acetyloxy)-3a-hydroxy-12-(hydroxymethyl)-2,5,8,8-tetramethyl-1h,2h,3h,4h,5h,9h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate
[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17s,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-12-oxo-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate
6-(but-2-en-2-yl)-3,9'-dihydroxy-10'-(hydroxymethyl)-7'-methoxy-5,6',14',16'-tetramethyl-2',20'-dioxaspiro[oxane-2,21'-tricyclo[17.3.1.0⁴,⁹]tricosane]-5',10',12',16'-tetraen-3'-one
(2s,3r,4s,5r)-2-{[(1r,3r,7r,9s,17r,18r,19r,21r,22r)-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxahexacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹²]tetracosa-4,11,14-trien-9-yl]oxy}oxane-3,4,5-triol
1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate
(1r,13r,15r)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
(1s,4s,5r,8r,10s,13s,14r,17s,18r,19s,20r)-4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
n-[2-({[(1s,2s,3s,4s,5r,6s,8s,9r,10s,13s,16r,17s)-11-ethyl-3,8,9-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]oxy}carbonyl)phenyl]ethanimidic acid
(1r,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate
(1r,2s,6s,8r,10s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icosan-19-yl (2e)-2-methylbut-2-enoate
6,7-dihydroxy-14-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-14-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
(1s,2r,3s,4s,5s,6s)-3-(acetyloxy)-5-[(3r,5s)-3,6-dihydroxy-6-methyl-5-[(2-methylpropanoyl)oxy]hept-1-en-2-yl]-2,6-dihydroxy-2-methyl-4-[(2-methylpropanoyl)oxy]cyclohexyl (2z)-2-methylbut-2-enoate
(2r,4as,6as,8ar,10s,12as,14as,14br)-10-{[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid
(1s,2r,3s,4s,5s,6s)-3-(acetyloxy)-5-[(3s,5s)-5,6-dihydroxy-6-methyl-3-[(2-methylpropanoyl)oxy]hept-1-en-2-yl]-2,6-dihydroxy-2-methyl-4-[(2-methylpropanoyl)oxy]cyclohexyl (2z)-2-methylbut-2-enoate
(1r,2r,5s,6r,10r,11s,12r,15r,16r,18s,19r)-16-(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-18-yl (2e)-3-phenylprop-2-enoate
n-[2-({[(1r,2r,3s,4s,5r,6s,8s,9s,10r,13s,16s,17s)-11-ethyl-2,3,8-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]oxy}carbonyl)phenyl]ethanimidic acid
{11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-12-oxo-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-aminobenzoate
(2s,3r,4s,5r)-2-[(1s,1'r,2r,4'r,5s,5'r,6'r,10's,12'r,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-eneoxy]oxane-3,4,5-triol
(3s,6s,9s,12s,15s)-6-benzyl-3,9-bis[(2r)-butan-2-yl]-15-[(2s)-butan-2-yl]-5,8,14-trihydroxy-12-isopropyl-10-methyl-1-oxa-4,7,10,13-tetraazacyclopentadeca-4,7,13-triene-2,11-dione
(9s,15as)-5,7-dihydroxy-3-(7-hydroxyoctan-2-yl)-6-methyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,4h,5h,6h,9h,12h,13h,14h,15h,15ah-pyrido[2,1-c]1-oxa-4,7-diazacyclododecane-1,10-dione
C34H52N2O7 (600.3774321999999)
n-[2-({[(1s,2s,3s,4s,5r,6s,8s,9r,10s,13s,16s,17s)-11-ethyl-3,8,9-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]oxy}carbonyl)phenyl]ethanimidic acid
(1r,2s,4r,5r,8r,9s,11s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2e,4z)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid
1,3-bis(acetyloxy)-5,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl deca-2,4-dienoate
1-[4-(3-hydroxy-4-methyl-5-oxooxolan-3-yl)-4-oxobutan-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl propanedioate
3-[(1'r,2s,2'r,3s,4s,5's,8'r,10'r,14'r,17'r,18'r)-2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy]-3-oxopropanoic acid
n-{2-[({11-ethyl-3,8,9-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}oxy)carbonyl]phenyl}ethanimidic acid
6-benzyl-5,8,14-trihydroxy-12-isopropyl-10-methyl-3,9,15-tris(2-methylpropyl)-1-oxa-4,7,10,13-tetraazacyclopentadeca-4,7,13-triene-2,11-dione
5-(acetyloxy)-14-(butanoyloxy)-6-hydroxy-3-isopropyl-10-methanesulfinyl-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate
9a,11a-dimethyl-1-{6-methyl-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]heptan-2-yl}-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol
1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate
6-{11-hydroxy-7-[(3-methoxy-3-oxopropanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-4-oxo-1h,2h,3h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid
(1r)-1-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione
(1r,4s,5r,8r,10s,13s,14r,19s,20s)-19-hydroxy-4,5,9,9,13,19,20-heptamethyl-10-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-21-oxahexacyclo[18.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracosa-15,17-dien-22-one
5,6-dihydroxy-16,16-dimethyl-13-[5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4,19-dihydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate
2-{4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-eneoxy}oxane-3,4,5-triol
(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione
n-[2-({[(1s,2r,3s,4s,5r,6s,8s,9r,10s,13s,16s,17s)-11-ethyl-2,3,8-trihydroxy-4,6,16-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]oxy}carbonyl)phenyl]ethanimidic acid
(1r,4s,5r,8r,10s,13s,14r,19s,20s)-19-hydroxy-4,5,9,9,13,19,20-heptamethyl-10-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-21-oxahexacyclo[18.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracosa-15,17-dien-22-one
1-(1r,3r,5s,6r)-6-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-(1r,3s,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (1r,2s,3s,4s)-3,4-diphenylcyclobutane-1,2-dicarboxylate
(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (4e)-deca-2,4-dienoate
(1s,3s,9r,11r)-7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-[(1e)-3-methylbuta-1,3-dien-1-yl]-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione
1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione
9'-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-8',10'-dihydroxy-3',3',4-trimethyl-11'-(3-methylbut-2-en-1-yl)-4',6'a-dihydro-3'ah-spiro[cyclohexane-1,1'-furo[3,4-e]xanthen]-3-ene-5,7'-dione
[(4ar,4bs,5r,7r,8ar,9s,10as)-7-ethenyl-5,8a-dihydroxy-1,1,7-trimethyl-9-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrophenanthren-4a-yl]methyl 3-hydroxy-3-methylbutanoate
6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-(nona-1,3-dien-1-yl)-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl propanoate
6,7-dihydroxy-16-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-16-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione
10-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid
(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate
3-(acetyloxy)-5-{3,6-dihydroxy-6-methyl-5-[(2-methylpropanoyl)oxy]hept-1-en-2-yl}-2,6-dihydroxy-2-methyl-4-[(2-methylpropanoyl)oxy]cyclohexyl 2-methylbut-2-enoate
1-(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-(1r,3r,5s,6r)-6-(propanoyloxy)-8-azabicyclo[3.2.1]octan-3-yl 3,4-diphenylcyclobutane-1,2-dicarboxylate
(2s,3r)-n-[(3r,4r,7r,10z)-5,8-dihydroxy-7-[(r)-hydroxy(phenyl)methyl]-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-2-(dimethylamino)-3-hydroxy-3-phenylpropanimidic acid
5,7-dihydroxy-3-(7-hydroxyoctan-2-yl)-6-methyl-9-({4-[(3-methylbut-2-en-1-yl)oxy]phenyl}methyl)-3h,4h,5h,6h,9h,12h,13h,14h,15h,15ah-pyrido[2,1-c]1-oxa-4,7-diazacyclododecane-1,10-dione
C34H52N2O7 (600.3774321999999)